Autolus Therapeutics (AUTL) Income towards Parent Company: 2017-2025
Historic Income towards Parent Company for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -$79.1 million.
- Autolus Therapeutics' Income towards Parent Company rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
- According to the latest figures from Q3 2025, Autolus Therapeutics' Income towards Parent Company is -$79.1 million, which was down 65.11% from -$47.9 million recorded in Q2 2025.
- In the past 5 years, Autolus Therapeutics' Income towards Parent Company registered a high of -$6.8 million during Q4 2021, and its lowest value of -$44.8 billion during Q3 2021.
- In the last 3 years, Autolus Therapeutics' Income towards Parent Company had a median value of -$52.7 million in 2024 and averaged -$56.9 million.
- As far as peak fluctuations go, Autolus Therapeutics' Income towards Parent Company crashed by 84,283.07% in 2021, and later spiked by 99.90% in 2022.
- Autolus Therapeutics' Income towards Parent Company (Quarterly) stood at -$6.8 million in 2021, then plummeted by 298.16% to -$27.0 million in 2022, then tumbled by 186.04% to -$77.2 million in 2023, then spiked by 64.23% to -$27.6 million in 2024, then grew by 3.63% to -$79.1 million in 2025.
- Its Income towards Parent Company stands at -$79.1 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$70.2 million for Q1 2025.